ArticleO&G open2026
Postpartum Long-Acting Reversible Contraception Use Among People With Sickle Cell Disease in the United States.
Article in O&G open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess trends in the uptake of immediate postpartum long-acting reversible contraception (LARC) among deliveries among people with and without sickle cell disease (SCD).
methodsUsing 2012-2019 National Inpatient Sample data, we conducted a cross-sectional study comparing rates of immediate postpartum LARC uptake (intrauterine device or contraceptive implant) among all delivery hospitalizations (live-born and stillbirth deliveries) for people with SCD and people without SCD. We included analyses of all deliveries and a subanalysis limited to individuals of Black race as per dataset coding. We calculated the rates of immediate postpartum LARC uptake among people with and without SCD per 1,000 deliveries. We used univariate and multivariate logistic regression to evaluate the odds of immediate postpartum LARC uptake by SCD status, adjusting for covariates including clinical characteristics (ie, delivery mode and presence of severe maternal morbidity [SMM]), and demographic factors (ie, maternal age, insurance, household income, region, hospital type, and calendar year).
resultsWe analyzed 29,822,518 deliveries between 2012 and 2019: 18,860 among people with SCD and 29,803,658 among people without SCD. Overall, people with SCD had higher rates of SMM and were more likely to deliver at an urban hospital, to use public insurance, and to deliver in the South compared with those without SCD. Compared to people without SCD, people with SCD had a threefold higher uptake of immediate postpartum LARC (16.4 per 1,000 deliveries vs 4.7 per 1,000 deliveries,
conclusionAfter adjustment for clinical and demographic factors, immediate postpartum LARC use was higher among people with SCD compared with people without SCD. These results reflect nuanced patterns of contraception use for people who experience high-acuity outcomes in pregnancy and invite further inquiry on drivers for immediate postpartum contraception decision making in medically complex patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.